By Colin Kellaher

 

Shares of Insulet Corp. rose nearly 10% on Friday after the medical-device company won U.S. Food and Drug Administration approval for its Omnipod 5 automated insulin-delivery system for individuals ages 6 and older with type 1 diabetes.

The FDA nod represents a meaningful milestone for Insulet, said analysts at Citi, who noted that the Acton, Mass., company and its investors have been waiting for a green light for almost a year.

Citi said it believes the Omnipod 5, which is the first tubeless automated insulin-delivery system that integrates with DexCom Inc.'s G6 continuous glucose monitoring system and a compatible smartphone, will be very well received, and the analysts reiterated their buy rating on the stock.

Insulet shares were recently changing hands at $213.12, up 9.4%.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 28, 2022 10:25 ET (15:25 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Insulet Charts.
Insulet (NASDAQ:PODD)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Insulet Charts.